Abstract 2022P
Background
Due to its devastating behavior and unfavorable prognosis, SCLC is the most recalcitrant lung neuroendocrine tumor to treat. Performance status (PS), stage, and liver metastases have historically been recognized as prognostic factors in SCLC. However, these variables are unable to adequately stratify patients. Recently, we found that the laterality of primary lesions independently affected the outcome of well-differentiated lung neuroendocrine tumors, with left typical/atypical carcinoids having the worse prognosis (La Salvia A, et al. Endocrine 2022). The present analysis aims to evaluate the prognostic significance of laterality in SCLC patients.
Methods
Consecutive patients with histologically confirmed diagnosis of SCLC treated according to disease stage at 3 different Institutions from January 2020 to December 2022 and with a follow-up period of ≥ 3 months were included. Clinical and disease characteristics, date of progression, and death were collected and analyzed.
Results
A total of 140 patients were analyzed. The majority were male (57.1%), and former/current smokers (99.3%) with stage IV disease (88.5%). Primary tumor was in the right lung in 76 cases (54.2%). As expected, ECOG PS, stage, and liver metastases were significantly associated with overall survival. With a median follow-up of 11 months (range 3-28 months), patients with primary tumors in the right lung had longer survival than patients with primary tumors in the left lung (12.0 versus 9.5 months, p=0.003; HR 2.020). Similar results were observed by excluding patients with stage III disease (11.5 versus 8.8 months, p< 0.0001; HR 2.532). A multivariate model, including all significant variables in the univariate model, confirmed that left laterality represented an independent negative prognostic factor (p=0.044 in the overall population and p=0.007 considering only stage IV).
Conclusions
Our analysis showed the prognostic relevance of primary tumor laterality in SCLC for the first time. Biological differences related to differential exposure to carcinogens in tissue specimens is ongoing.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
L. Landi: Non-Financial Interests, Personal, Speaker, Consultant, Advisor: Pfizer, Roche, MSD, BMS, Lilly, Amgen, Sanofi; Non-Financial Interests, Personal, Invited Speaker: Takeda, Novartis. A. Tufman: Non-Financial Interests, Personal, Speaker, Consultant, Advisor: Daiichi Sankyo, AstraZeneca, BMS, Boehringer Ingelheim, Amgen, GSK, Lilly, Bayer, Pfizer, Sanofi, Roche, Takeda, MSD. G. Minuti: Non-Financial Interests, Personal, Speaker, Consultant, Advisor: Roche, BMS, AstraZeneca, Novartis, Sanofi; Non-Financial Interests, Personal, Advisory Role: Gilead. D. Kauffmann-Guerrero: Non-Financial Interests, Personal, Speaker, Consultant, Advisor: AstraZeneca, Boehringer Ingelheim, Roche, MSD, Pfizer, BMS, GSK, Novartis, Takeda, Sanofi, Janssen. T.A. Bolt: Non-Financial Interests, Personal, Speaker, Consultant, Advisor: Lilly Germany. F.L. Cecere: Non-Financial Interests, Personal, Speaker, Consultant, Advisor: Amgen, Novartis, AstraZeneca, Takeda, Roche. F. Cappuzzo: Non-Financial Interests, Personal, Speaker, Consultant, Advisor: Roche, AstraZeneca, BMS, MSD, Lilly, Bayer, Takeda, PharmaMar, Novartis, Merck, Janssen. All other authors have declared no conflicts of interest.
Resources from the same session
2007P - Real-world (rw) outcomes to chemoimmunotherapy and biomarker analysis in extensive-stage small cell lung cancer (ES SCLC)
Presenter: Emmanouil Panagiotou
Session: Poster session 05
2008P - Brazilian real-world data of immunotherapy (IO) in extensive disease small cell lung cancer (ES-SCLC)
Presenter: Flávia Duarte
Session: Poster session 05
2009P - CNS efficacy of immune checkpoint inhibitors when combined to stereotactic radiosurgery in extensive stage small cell lung cancer
Presenter: Muhammad Awidi
Session: Poster session 05
2010P - Non-invasive radiomics signature predicts response to combination chemoimmunotherapy in extensive-stage small cell lung cancer (ES SCLC)
Presenter: Stuthi Perimbeti
Session: Poster session 05
2011P - Machine-derived features of tumor infiltrating lymphocytes (TILs) as biomarkers of clinical outcomes to platinum chemotherapy in small cell lung cancer (SCLC)
Presenter: Prantesh Jain
Session: Poster session 05
2012P - Spatially resolved transcriptomics deciphers inter- and intra-tumor heterogeneity of small cell lung cancer
Presenter: xujie Sun
Session: Poster session 05
2013P - Investigating the clinical relevance of immune checkpoint expression in the peripheral blood of patients with small cell lung cancer (SCLC)
Presenter: Dimitrios Mavroudis
Session: Poster session 05
2014P - ATR inhibition upregulates PD-L1 and potentiates the antitumor immune response to chemoimmunotherapy in small cell lung cancer
Presenter: Triparna Sen
Session: Poster session 05
2015P - Association between gene characteristics and mutation abundance with the prognosis of small cell lung cancer
Presenter: Lian Yu
Session: Poster session 05
2016P - The role of galectin-1 in SCLC: Prognostic significance and therapeutic implications
Presenter: Arancha Cebrian
Session: Poster session 05